image

FIND A COURSE

  • The ASAM National Practice Guideline Special Populations Webinar (October)

    Includes a Live Event on 10/25/2016 at 3:00 PM (EDT)

    Adolescents - This webinar will provide important recommendations to help clinicians treat adolescents who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    The treatment of adolescents with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents with opioid use disorder often benefit from services designed specifically for them. The Adolescents Webinar will provide an overview of the recommendation and in-depth information treating adolescents from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for adolescents.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Marc Fishman

    MD, DFASAM

    Marc Fishman MD is board certified in addiction psychiatry and addiction medicine. A faculty member of the Johns Hopkins University School of Medicine, he is Medical Director and CEO of Maryland Treatment Centers, a regional behavioral health care provider, with inpatient and outpatient facilities for adolescents and adults. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and co-occurring disorders. He has been principal investigator or collaborator for several NIDA- and CSAT-funded projects to improve and evaluate adolescent treatment, as well as pharmacotherapy trials in adults. He is the author of numerous articles and book chapters on addiction treatment, and lectures widely on a variety of topics including adolescent treatment, youth opioid treatment, placement and treatment matching strategies. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM National Practice Guideline Special Populations Webinar (September)

    Includes a Live Event on 09/27/2016 at 12:00 PM (EDT)

    Individuals with Pain - This webinar will provide important recommendations to help clinicians treat individuals with pain who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    The occurrence of acute and chronic pain among patients with an opioid use disorder is not uncommon. Because of the current epidemic of nonmedical prescription drug use, it is critical to know how to manage pain safely and effectively. The Individuals with Pain Webinar will provide an overview of the recommendations and in-depth information on treating individuals with pain from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for individuals with pain.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Yngvild Olsen

    MD, MPH, FASAM

    Yngvild Olsen, MD, MPH, currently serves as Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services, a comprehensive outpatient Opioid Treatment Program in Baltimore City. She completed her medical training at Harvard Medical School, and internal medicine residency with a year as Primary Care Chief Resident at the Boston Medical Center. She received a Master's in Public Health from the Johns Hopkins University Bloomberg School of Public Health as part of a fellowship in General Internal Medicine at the Johns Hopkins School of Medicine. She has previously served as the Vice President of Clinical Affairs for the Baltimore Substance Abuse Systems, as the Deputy Health Officer for the Harford County Health Department, and as the Medical Director for the Johns Hopkins Hospital's outpatient substance use treatment services. Dr. Olsen's advocacy work includes serving as the President of the Maryland Society of Addiction Medicine (MDSAM), as the President of the Maryland Association for the Treatment of Opioid Dependence (MATOD), and as a member of several boards and councils, including the Maryland Overdose Prevention Advisory Council, the Journey Home Board, Baltimore's effort to end homelessness, and the National Council on Alcoholism and Other Drug Dependence-Maryland chapter board. She also proudly looks forward to serving as a recently elected At-Large Member to the ASAM Board of Directors for 2015-2017.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM National Practice Guideline Special Populations Webinar (August)

    Includes a Live Event on 08/30/2016 at 3:00 PM (EDT)

    Individuals in the Criminal Justice System - This webinar will provide important recommendations to help clinicians treat individuals in the criminal justice system with opioid use disorder who have complex medical and environmental needs.

    This webinar will be recorded for archived viewing.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. Prison drug use is particularly risky because of the environment. The high concentration of at-risk individuals and general overcrowding can increase the risk of adverse consequences associated with drug use, including violence, drug-related deaths, suicide, and self-harm. The Individuals in the Criminal Justice System webinar will provide an overview of the recommendations and in-depth information on treating individuals in the criminal justice system from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for individuals in the criminal justice system.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Aaron D. Fox

    MD, MS

    Aaron Fox is an Assistant Professor of Medicine in the Division of General Internal Medicine at Albert Einstein College of Medicine/Montefiore Medical Center. Dr. Fox is a primary care physician and is Board Certified in Addiction Medicine. He completed residency training at Montefiore in the Primary Care/Social Medicine Residency Program and also received a Master's Degree in Clinical Research Methods from Einstein. Dr. Fox is the Co-Director of the Bronx Transitions Clinic, which provides medical care to patients who have recently been released from jail or prison. He also conducts research, funded by the National Institute on Drug Abuse, on opioid use disorder and the criminal justice system, developing behavioral interventions to complement buprenorphine treatment for opioid use disorder; and studying linkage to medical care following release from jail or prison.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • What Raising the Buprenorphine Cap Means for ASAM Members

    Learn about the most recent developments with the new buprenorphine limit, the qualifications needed for prescribing, what a “qualified practice setting” is, and how ASAM members and other doctors may be affected by this recent development.

    WHAT: This one-hour webinar provides an overview of the qualifications, requirements and processes related to applying for and maintaining the higher patient limit, as well as specific implications for ASAM members. Importantly, the webinar addresses practice management issues such as documenting a diversion control plan, demonstrating adherence to evidence-based guidelines, and formalizing agreements with behavioral health service providers.

    WHO: Physicians interested in applying for the higher limit, as well as their practice managers and care team.

    WHY: Evaluate your qualifications for the limit increase and prepare for the application and reporting processes.

    R. Corey Waller

    MD, MS, FACEP, DFASAM

    R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neu-omolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.

    Jinhee Lee

    Senior Public Health Advisor, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration

    CDR Jinhee Lee, PharmD, is a Senior Public Health Advisor in the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration (SAMHSA). She is the co-lead for SAMSHA's Prescription Drug Abuse initiative and the project officer for two SAMHSA PDMP EHR cooperative agreement programs. She has also served as a core member of the Office of the National Coordinator for Health Information Technology's project to improve access to PDMP through Health Information Technology for the last few years.

    Prior to joining SAMHSA, CDR Lee was a Senior Regulatory Review Officer at the FDA and also previously worked as a clinical pharmacist at the Washington Hospital Center. She earned her Bachelor of Science degree from the University of California, Los Angeles, Doctor of Pharmacy degree from the University of Illinois, ASHP Pharmacy Practice Residency at the Washington Hospital Center, and an Executive Fellowship in Patient Safety through the Virginia Commonwealth University.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
    • More Information
  • The ASAM National Practice Guideline Special Populations Webinar (July)

    Recorded On: 07/26/2016

    Pregnant Women - This webinar will provide important recommendations to help clinicians treat pregnant women with opioid use disorder who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    Many of the medical risks associated with opioid use disorder are similar for both pregnant and non-pregnant women. However, opioid use disorder carries obstetrical risks for pregnant women. The Pregnant Women Webinar will provide an overview of the recommendations and in-depth information on treating pregnant women from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for pregnant women.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair, Reviewer None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Tricia Wright

    MD, MS, FACOG, FASAM

    Tricia Wright, MD MS is an assistant professor of Obstetrics, Gynecology and Women's Health at the University of Hawaii John A. Burns School of Medicine and founder, former medical director, and now Women's Health Liaison of the PATH Clinic, an outreach clinic of Waikiki Health Center, which provides prenatal, postpartum and family planning to women with a history of substance use disorders. She is board certified in both Ob/Gyn and Addiction Medicine and a Fellow of the American College of Obstetrics and Gynecology. She has been waivered to provide buprenorphine since 2009, and has treated both pregnant and non-pregnant women. She won funding approval in 2006 from the Hawaii legislature to start a perinatal clinic for women with substance use, the first in the state. The Path Clinic opened in 2007, and has seen over 400 pregnant women since that time. She completed her Masters Degree in Clinical Research from the University of Hawaii in 2009, her thesis paper studying the disparities of smoking and drug use rates during pregnancy of Native Hawaiian women. Her research interests include substance use disorders among pregnant women, including barriers to family planning, screening, brief intervention and referral to treatment (SBIRT), best practices for treatment, and the effects of methamphetamine, marijuana and tobacco on the placenta.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
    • More Information

UPCOMING LIVE

The ASAM State of the Art Course in Addiction Medicine

October 6 - 8, 2016 | Washington Hilton | Washington, DC


The ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

April 6-9, 2017 | New Orleans Hilton | New Orleans, LA